A 43-year-old woman with well-controlled HIV was prescribed a 6-month course of isoniazid preventative therapy (IPT) (300 mg daily) and pyridoxine (50 mg daily) for latent tuberculosis as part of a nationwide effort in Uganda to decrease the burden of tuberculosis among persons with HIV [1]. Approximately 4 months later, she developed symmetric, photo-distributed, well-demarcated, severely pruritic plaques with scale resembling peeling paint on her bilateral forearms, posterior neck, and upper back (Fig. 1). She denied gastrointestinal or neurologic symptoms. Before visiting the dermatology clinic, the working diagnosis of her primary provider was allergic contact dermatitis, but she remained untreated.
Fig. 1.
Well-demarcated plaques with “peeling paint” scale distributed symmetrically on sun-exposed sites.
Based on the morphology, distribution, and developmental time course of her rash, a clinical diagnosis of isoniazid-related pellagra was made. Given the high cost of niacin locally, a twice-daily B complex multivitamin containing 7.5 mg niacinamide was prescribed. Topical betamethasone ointment twice daily was given for pruritus. Her IPT was also stopped, as she had received five of six months of the planned course. One month later, her rash had completely resolved, leaving behind post-inflammatory hyperpigmentation and mild, steadily improving residual pruritus.
Pellagra is a clinical syndrome caused by vitamin B3 (niacin) deficiency. Although classically associated with altered vitamin B6 (pyridoxine) metabolism, isoniazid also interferes indirectly with the conversion of tryptophan to nicotinamide [2]. Isoniazid may therefore cause pellagra despite pyridoxine supplementation. This is especially relevant in settings where maize is the staple dietary carbohydrate for the population [3]. If available, clinicians practicing in such areas should consider obtaining baseline tryptophan and nicotinamide serum levels and initiating B complex vitamin and/or nicotinamide supplementation at the onset of IPT.
In settings planning broad IPT implementation, patients should be educated about possible adverse effects of isoniazid, and physicians should be comfortable recognizing and treating these, including pellagra. Isoniazid-related pellagra usually resolves after the offending medication is stopped. For patients that must continue IPT, nicotinamide or a B complex multivitamin, in addition to dietary counseling regarding niacin-rich food sources (including beef liver, chicken breast, marinara sauce, tuna fish, brown rice, and peanuts) [4], are appropriate initial steps. Medium- to high-potency topical corticosteroid ointment can help relieve symptoms while the underlying cause is being addressed. For those with severe symptoms refractory to these measures, physicians should consider premature termination of IPT followed by careful monitoring for signs of active TB. Alternative regimens such as rifampin, which is associated with greater completion rates and less hepatotoxicity compared to isoniazid [5], should also be considered.
Informed consent
Written informed consent was obtained from the patient for publication of this case report and accompanying images. A copy of the written consent is available for review by the Editor-in-Chief of this journal on request
CRediT authorship contribution statement
Sarah J. Coates: Conceptualization, Writing - original draft. Amy W. Blasini: Writing - review & editing, Resources. Patrick Musinguzi: Writing - review & editing. Miriam Laker-Oketta: Supervision, Writing - review & editing.
Acknowledgements
Dr. Sarah J Coates was supported by the National Cancer Institute and the Fogarty International Center of the National Institutes of Health (NIH) under Award Number D43TW009343 as well as the University of California Global Health Institute (UCGHI). The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH or UCGHI.
Amy W. Blasini was supported by the Fogarty International Center of the National Institutes of Health under grant number D43TW009345 awarded to the Northern Pacific Global Health Fellows Program. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.
References
- 1.Ministry of Health Uganda . 2016. Uganda clinical guidelines 2016. [Google Scholar]
- 2.Darvay A., Basarab T., McGregor J.M., Russell-Jones R. Isoniazid induced pellagra despite pyridoxine supplementation. Clin Exp Dermatol. 1999;24(3):167–170. doi: 10.1046/j.1365-2230.1999.00444.x. [DOI] [PubMed] [Google Scholar]
- 3.Kipsang J.K., Choge J.K., Marinda P.A., Khayeka-Wandabwa C. Pellagra in isoniazid preventive and antiretroviral therapy. IDCases. 2019;17:e00550. doi: 10.1016/j.idcr.2019.e00550. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 4.U.S. Department of Agriculture . 2019. FoodData central. [Online]. Available: https://fdc.nal.usda.gov/. [Accessed: 19 March 2020] [Google Scholar]
- 5.Ronald L.A. Treatment with isoniazid or rifampin for latent tuberculosis infection: Population-based study of hepatotoxicity, completion, and costs. Eur Respir J. 2020;(January 24) doi: 10.1183/13993003.02048-2019. [Epub ahead of print], p. 1902048. [DOI] [PubMed] [Google Scholar]